U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H23N3O4S
Molecular Weight 341.426
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOSULPIRIDE

SMILES

CCN1CCC[C@H]1CNC(=O)C2=CC(=CC=C2OC)S(N)(=O)=O

InChI

InChIKey=BGRJTUBHPOOWDU-NSHDSACASA-N
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H23N3O4S
Molecular Weight 341.426
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://medind.nic.in/daa/t07/i2/daat07i2p144.pdf | http://www.druginfosys.com/drug.aspx?drugcode=1180&type=1

Levosulpiride [RV 12309, L-sulpiride, levosulpride, Dislep® 25, Levopride®, Levopraid®] is a potent dopamine D2 receptor blocker that was originated by Ravizza Farmaceutici (now AbbVie). Levosulpiride is the levo enantiomer of sulpiride. The levo enantiomer shows better/similar pharmacological actions and lower incidence of toxic effects than both dextro as well as the racemic forms of the drug. Levosulpiride is marketed in Italy and South Korea, and is possibly available elsewhere in Europe and Asia. Levosulpiride does not appear to be available in North America. Levosulpiride is available as 25mg tablets, drops and in ampoules for parenteral administration. Generic versions of levosulpiride also appear to be available in some countries. Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
51.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Levopraid

Approved Use

Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
Primary
Unknown

Approved Use

Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
Primary
Levopraid

Approved Use

Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
Primary
Levopraid

Approved Use

Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
Primary
Unknown

Approved Use

Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
PubMed

PubMed

TitleDatePubMed
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
1992 Apr 10
A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives.
1993 Dec
Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
1994 Jan
A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
1995 Sep-Oct
Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
1996 Dec
Side-effects of benzamide derivatives.
1997 Jan
5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract.
2003 Apr
Improvement of vestibular compensation by Levo-sulpiride in acute unilateral labyrinthine dysfunction.
2004 Apr
Delayed Gastric Emptying in Functional Dyspepsia.
2004 Aug
Type 1 (insulin-dependent) diabetes mellitus and gastric emptying: role of blood glucose concentration and dopamine D2 receptors.
2004 Feb
Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.
2004 Feb 15
Development of HPLC method for the determination of levosulpiride in human plasma.
2004 Jun 29
Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
2004 Mar
The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.
2004 Nov 20
Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma.
2004 Oct 5
BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
2005
The analysis of characteristics of elderly people with high VSC level.
2005
Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol.
2005 Feb
[Two cases of tardive Tourette syndrome].
2006
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
2006 Feb 28
Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.
2006 Mar
Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials.
2007
[The effect of sulpirid in treatment of patients with gastric and duodenal erosions and ulcers].
2007
[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease].
2007
Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding.
2007
The effect of levosulpiride in burning mouth syndrome.
2007 Jan-Feb
Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia.
2007 Mar
Clinical outcome of rumination syndrome in adults without psychiatric illness: a prospective study.
2007 Nov
Drug-induced and psychogenic resting suprahyoid neck and tongue tremors.
2008 Apr 15
Triple reuptake inhibitors: the next generation of antidepressants.
2008 Dec
[Major gastrointestinal syndromes (2): dyspepsia or syndrome of the upper digestive system related with food (2)].
2008 Jul-Sep
Long-term Ultrasonographic Follow-up Study of Gastric Motility in Patients with Functional Dyspepsia.
2008 Mar
Triple reuptake inhibitors: a premise and promise.
2008 Sep
Levosulpiride-induced resting orolingual tremor.
2009 Aug 15
Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study.
2009 Dec
Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia.
2009 Feb
Teratogenicity and hyperprolactinemia.
2009 Jan
[Efficiacy of combined eglonil and avestin administration for pharmacocorrection of depressive disorders in women with hypoestrogenic syndrome].
2009 Jul-Aug
Determination of metoclopramide in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry.
2009 Jun 15
Associations among hair loss, oral sulfur-containing gases, and gastrointestinal and metabolic linked diseases in Japanese elderly men: pilot study.
2009 Mar 13
Levosulpiride-induced movement disorders.
2009 Nov 15
Gastroparesis: current concepts and management.
2009 Sep
Diabetes mellitus and drug-induced Parkinsonism: a case-control study.
2009 Sep 15
Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression.
2010
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects.
2010 Aug 11
Liquid chromatography-tandem mass spectrometry quantification of levosulpiride in human plasma and its application to bioequivalence study.
2010 Aug 15
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.
2010 Jan
Pharmacotherapy for gastroparesis: an attempt to evaluate a safer alternative.
2010 Oct
[Levosulpiride in the management of functional dyspepsia and delayed gastric emptying].
2010 Oct
Levosulpiride in premature ejaculation.
2010 Oct-Dec
Patents

Patents

Sample Use Guides

dosage depends on indication: 200 to 800 mg, 24 hourly, IM; 200 to 400 mg, 12 hourly, PO; 25 mg, 8 hourly, PO
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:07:37 UTC 2023
Edited
by admin
on Fri Dec 15 16:07:37 UTC 2023
Record UNII
JTG7R315LK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOSULPIRIDE
INN   MART.   WHO-DD  
INN  
Official Name English
SULPIRIDE, (S)-
Common Name English
LEVOPRAID
Brand Name English
SULPIRIDE L-FORM [MI]
Common Name English
(-)-N-(((S)-1-ETHYL-2-PYRROLIDINYL)METHYL)-5-SULFAMOYL-O-ANISAMIDE
Common Name English
S-(-)-SULPIRIDE
Common Name English
levosulpiride [INN]
Common Name English
BENZAMIDE, 5-(AMINOSULFONYL)-N-(((2S)-1-ETHYL-2-PYRROLIDINYL)METHYL)-2-METHOXY-
Systematic Name English
SULPIRIDE L-FORM
MI  
Common Name English
LEVOBREN
Brand Name English
SULPIRIDE, (-)-
Common Name English
LESURIDE
Brand Name English
LEVOPRIDE
Brand Name English
LEVOSULPIRIDE [MART.]
Common Name English
Levosulpiride [WHO-DD]
Common Name English
(-)-SULPIRIDE
Common Name English
L-SULPIRIDE
Common Name English
Classification Tree Code System Code
WHO-ATC N05AL07
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
WHO-VATC QN05AL07
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID0042583
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
CAS
23672-07-3
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
MERCK INDEX
m10389
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY Merck Index
SMS_ID
100000082285
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
INN
6593
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
NCI_THESAURUS
C90840
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
FDA UNII
JTG7R315LK
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
IUPHAR
958
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
CHEBI
64119
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL267044
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
DRUG CENTRAL
1577
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
MESH
C078143
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
EVMPD
SUB08494MIG
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
WIKIPEDIA
LEVOSULPIRIDE
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
PUBCHEM
688272
Created by admin on Fri Dec 15 16:07:37 UTC 2023 , Edited by admin on Fri Dec 15 16:07:37 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY